New Levels of Allergy Management: Furry Animals
An allergy diagnosis is based on the history, clinical symptoms and physical examination of the patient in combination with results of sIgE tests.
ImmunoCAP® Molecular Allergology takes the diagnosis and management of allergy to a whole new level. The technology uses single allergen components to quantitatively detect IgE antibodies. A single blood sample enables measurement to all available ImmunoCAP components, providing precise results for better risk assessment. ImmunoCAP Allergen Components help differentiate “true” allergies from symptoms due to cross-reactivity, evaluate the risk of severe reactions and help in defining the optimal specific immunotherapy treatment. Benefits that ultimately can improve the patient’s quality of life.
The case history of pet allergic patients does not always clearly suggest which animal(s) is causing the symptoms. Furthermore, 60-70% of animal allergic patients are sensitized to several pets such as cat, dog and horse.
Components can help explain multiple positive pet extract tests and clarify if they are due to true co-sensitization or to cross reactivity between serum albumins.
Specific pet components discriminate between true sensitization to one/several pets:
- Specific cat components: Fel d 1, Fel d 4
- Specific dog components: Can f 1, Can f 2, Can f 5
- Specific horse component: Equ c 1
Cross-reactive pet components explain cross-reactivity:
- Serum albumins: cat component Fel d 2, dog component Can f 3
- Serum albumins are present in all mammals and have similar protein structure between species
A better differentiation helps give relevant advice and define the optimal treatment. Thus, component testing can contribute to improved quality of life for the patient.